Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2016-08-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
第三届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the approval of the company's 2016 semi-annual report, investment decisions, and branch office cancellation. The document does not contain the full semi-annual report or detailed financial statements but rather announces the resolutions passed regarding these matters. It references the semi-annual report and other announcements available elsewhere, indicating this is a meeting resolution announcement rather than the report itself. The document length is short (1572 characters), and it serves as an official announcement of decisions made by the Supervisory Board. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2016-08-22 Chinese
关于参与发起设立人寿保险股份有限公司的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the progress of its participation in the establishment of a life insurance company. It includes details about regulatory approval from the China Insurance Regulatory Commission, the company's board resolutions, and potential risks related to the investment. The document is relatively short (1944 characters) and serves as a progress update or announcement rather than a full financial report or detailed filing. It does not contain financial statements, audit information, or detailed management discussion. It is not a report publication announcement since it contains substantive information about the approval and risks. The content fits best under a general regulatory announcement category about corporate developments and regulatory approvals. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2016-08-05 Chinese
关于子公司接受政府以股权投资方式有偿资助的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding its subsidiary receiving a government equity investment as a form of compensated subsidy. It details the transaction parties, the terms of the equity investment, the impact on the company's shareholding structure, and the financial indicators of the subsidiary. The document is relatively short (3121 characters) and primarily serves as a disclosure of a capital investment event rather than a full financial report or detailed analysis. It does not contain comprehensive financial statements or management discussion but focuses on the capital injection and related agreements. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2016-05-27 Chinese
2015年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "Annual Equity Distribution Implementation Announcement" for the year 2015 by Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the dividend distribution plan approved at the 2015 Annual General Meeting held on April 15, 2016, including dividend amounts, record dates, and payment methods. The document is an announcement of the implementation of the dividend distribution plan, not the dividend notice itself nor the full annual report. The document length is 2260 characters, which is relatively short and consistent with an announcement rather than a full report. It explicitly states the dividend distribution plan has been approved and is now being implemented, which fits the definition of a Notice of Dividend Amount (DIV). Therefore, the document is best classified as a Notice of Dividend Amount (DIV).
2016-04-25 Chinese
关于子公司投资入伙新余博大恒康投资管理中心（有限合伙）的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding an investment by a subsidiary of Shenzhen Salubris Pharmaceuticals Co., Ltd. into a partnership investment management center. It details the transaction overview, parties involved, investment purpose, impact, and risk warnings. The document is structured as a formal announcement to shareholders and the public, including assurances about the accuracy of information and compliance with regulatory requirements. It does not contain financial statements, detailed financial performance data, or management discussion and analysis. The document is about a capital investment transaction and does not fit the categories of annual reports, interim reports, earnings releases, or management reports. It is not a call transcript, audit report, or legal proceeding update. The content is focused on a financing/investment update by the company. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 4043 characters, which is consistent with an announcement rather than a full report.
2016-04-22 Chinese
2016年第一季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2016 年第一季度报告正文" which translates to "2016 First Quarter Report". It contains detailed financial data such as revenue, net profit, cash flow, earnings per share, and asset information for the first quarter of 2016. It also includes sections on shareholder changes, important matters, financial statement changes, and management commitments. The length of the document (10,797 characters) and the presence of substantive financial data and analysis confirm it is a comprehensive quarterly financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2016
2016-04-18 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.